d3-testosterone

d3-testosterone (AVA-291) is a novel, structurally identical form of testosterone in which select hydrogen atoms have been replaced with deuterium, resulting in a molecule designed to resist conversion into estradiol via the aromatase enzyme[7][8]. This modification specifically addresses a major safety concern in testosterone replacement therapy for women, where conversion to estrogen is linked to a potential increased risk of breast cancer recurrence or progression[7]. AVA-291 is described as a non-aromatizing androgen intended to mimic the efficacy of testosterone while potentially offering a safer profile for postmenopausal women and those with estrogen receptor-positive breast cancer risk[7]. The drug is being developed by Aviva Biosciences and is currently in the preclinical stage for indications including breast cancer and menopausal syndrome[1][8].

Other names

d3-Td-3-Td 3-TAVA-291AVA291AVA 291